Frontiers in Immunology (Nov 2022)

A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients

  • Claire Tardiveau,
  • Claire Tardiveau,
  • Guillaume Monneret,
  • Guillaume Monneret,
  • Anne-Claire Lukaszewicz,
  • Anne-Claire Lukaszewicz,
  • Valérie Cheynet,
  • Valérie Cheynet,
  • Elisabeth Cerrato,
  • Elisabeth Cerrato,
  • Katia Imhoff,
  • Katia Imhoff,
  • Estelle Peronnet,
  • Estelle Peronnet,
  • Maxime Bodinier,
  • Maxime Bodinier,
  • Louis Kreitmann,
  • Louis Kreitmann,
  • Sophie Blein,
  • Sophie Blein,
  • Jean-François Llitjos,
  • Jean-François Llitjos,
  • Jean-François Llitjos,
  • Filippo Conti,
  • Filippo Conti,
  • Morgane Gossez,
  • Morgane Gossez,
  • Marielle Buisson,
  • Hodane Yonis,
  • Martin Cour,
  • Laurent Argaud,
  • Marie-Charlotte Delignette,
  • Florent Wallet,
  • Frederic Dailler,
  • Céline Monard,
  • Karen Brengel-Pesce,
  • Karen Brengel-Pesce,
  • Fabienne Venet,
  • Fabienne Venet,
  • the RICO study group

DOI
https://doi.org/10.3389/fimmu.2022.1022750
Journal volume & issue
Vol. 13

Abstract

Read online

Immune responses affiliated with COVID-19 severity have been characterized and associated with deleterious outcomes. These approaches were mainly based on research tools not usable in routine clinical practice at the bedside. We observed that a multiplex transcriptomic panel prototype termed Immune Profiling Panel (IPP) could capture the dysregulation of immune responses of ICU COVID-19 patients at admission. Nine transcripts were associated with mortality in univariate analysis and this 9-mRNA signature remained significantly associated with mortality in a multivariate analysis that included age, SOFA and Charlson scores. Using a machine learning model with these 9 mRNA, we could predict the 28-day survival status with an Area Under the Receiver Operating Curve (AUROC) of 0.764. Interestingly, adding patients’ age to the model resulted in increased performance to predict the 28-day mortality (AUROC reaching 0.839). This prototype IPP demonstrated that such a tool, upon clinical/analytical validation and clearance by regulatory agencies could be used in clinical routine settings to quickly identify patients with higher risk of death requiring thus early aggressive intensive care.

Keywords